
Lung Biopsy for Lung Cancer
Key takeaways
A lung biopsy may be used to diagnose lung cancer. There are many kinds of lung biopsies, but common ones include needle, transbronchial, and open.
In some cases, prior tests like chest X-rays or CT scans indicate lung cancer may be present, and a lung biopsy may confirm a diagnosis.
Scans like a CT scan, MRI scan, or chest X-ray scan may show signs of cancer. If your doctor suspects cancer, a lung biopsy is often used to confirm the diagnosis.
A biopsy is a relatively quick procedure that can cause mild discomfort. There are a few different types, but a needle biopsy is one of the most common.
Read on to learn more about lung biopsies, how long they take, and what happens when the test is over.
How long does a lung cancer biopsy take?
There are different types of lung biopsies, and each may take varying amounts of time.
Needle lung biopsy
A needle biopsy, also called a percutaneous biopsy, means that a doctor will place a needle through the skin and into the lung. Then, they'll draw out a small tissue sample.
This procedure takes place under local anesthesia and uses either an ultrasound or CT scanner as a guide. Cancer Research UK reports that a needle lung biopsy usually takes 30 to 45 minutes.
Transbronchial biopsy
A transbronchial biopsy uses a flexible tube called a bronchoscope to take a sample of tissue from the lungs. The tube is inserted through the nose or mouth and down into the lungs.
This procedure involves sedation and usually takes about an hour.
Open lung biopsy
An open lung biopsy involves making an incision in the side of the body toward the back of the lung. A sample of tissue from the lungs is taken, and the incision is closed with stitches.
During this procedure, a chest drain is also inserted to help in the expansion of the lungs during the procedure to allow fluid to drain out. You'll be under anesthesia, and you may need to wait a bit before you can go home.
How long does it take to get lung biopsy results?
Once a sample is taken from a lung biopsy, it's sent to a laboratory for testing.
At the laboratory, a doctor called a pathologist will conduct tests on the sample to determine whether cancer cells are present. During this process, the pathologist may also conduct tests to help classify the type of cancer.
Results will then be detailed in a pathology report and sent to your doctor. This report is usually available within a week of the lung biopsy, and your doctor will call you with the results.
What does a lung biopsy show?
A lung biopsy doesn't technically 'show' anything. However, the tissue sample is tested to determine which type of cells are in your lungs.
If cancerous cells are present, the results can confirm a cancer diagnosis.
Is a lung biopsy painful?
Typically, a lung biopsy causes minor discomfort or no discomfort at all.
Sometimes, general anesthetic is used which means you'll be asleep and won't be aware of or feel anything that is happening. If you're not under a general anesthetic, a mild sedative may be administered to help you relax during the procedure.
A local anesthetic will be used to numb the area where the needle will be inserted. When this happens, you may feel a slight prick and pressure, but it shouldn't be painful.
Some biopsies, like an open biopsy, may require a few days' stay in the hospital. For other procedures with only a light sedative, you may be able to go home once the sedative wears off.
You might experience some slight pain at the site of the biopsy once local anesthesia begins to wear off. This will decrease with time, and you'll be given pain relief medication if needed.
Sharp pain or pain in the shoulders with breathing can be a sign of a collapsed lung. While uncommon, this can sometimes occur with a needle biopsy. Other symptoms of a collapsed lung may include:
rapid heart rate
shortness of breath
bluish tint to the skin
If you have any of these symptoms, you should seek immediate medical attention.
Can a lung biopsy cause cancer to spread?
Tumor seeding, also called needle seeding, is when a biopsy needle inserted into the body to sample a tumor dislodges cancer cells and allows them to spread along the track of the needle.
Studies on this have produced mixed results. While some instances of tumor seeding have been reported, including in lung cancer cases, it is very uncommon.
According to the National Cancer Institute, the chance of cancer spreading through a biopsy or surgical procedure is extremely low.
Physicians take steps to prevent the spread of cancer cells during biopsies and when removing tumors. For example, if taking tissue from more than one part of the body, different tools are used for each area.
Will my doctor help me plan my next steps after results?
Once your biopsy results arrive, your doctor will have a discussion with you about the next steps.
If cancer is found, more tests may be needed to determine the stage of cancer. Staging refers to the size of a tumor and the extent to which it has spread. Knowing the staging will help determine what treatment options may be best for you.
Your doctor will discuss the possible treatment options available to you as well as the pros and cons of each. They'll also discuss the goals of treatment. For instance, sometimes curing lung cancer completely isn't always a realistic goal, so treatment may be focused on controlling cancer and reducing symptoms.
It's important to ask questions during this period. It's also a good idea to get a second opinion if you'd like one.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Carilion Clinic Family Medicine in Weyers Cave is closing. What we know
The Weyers Cave location of Carilion Clinic Family Medicine will be closing effective July 8. "After careful consideration, we made the decision to close," said Hannah Curtis, a spokesperson for the Roanoke-based healthcare provider. "This will give providers and care teams additional support and resources as they transition to other nearby Carilion Family Medicine locations." Curtis said patient care will automatically transition with the providers, and they are working closely with patients ahead of July 8 to communicate changes. "If patients prefer to continue care with a different provider or at another location, they are welcome to choose from any of our nearby locations, including Bridgewater, Dayton, Fort Defiance, Staunton, and Waynesboro practices," Curtis said. Patients can contact the Weyers Cave care team at 540-234-9241 with any questions. More: Forum in Staunton to discuss how federal policies and budget cuts will impact education More: Will Churchville get fire station upgrades or a completely new station? — Patrick Hite is a reporter at The News Leader. Story ideas and tips always welcome. Connect with Patrick (he/him/his) at phite@ and on Instagram @hitepatrick. Subscribe to us at This article originally appeared on Staunton News Leader: Carilion Clinic Family Medicine in Weyers Cave to close July 8
Yahoo
34 minutes ago
- Yahoo
Middle East & Africa Point-of-Care Diagnostics Market Analysis Report 2025-2032 - Telemedicine and POC Convergence Unlock New Opportunities
The Middle East and Africa point-of-care diagnostics market is set for transformative growth, driven by rising demand for rapid and accurate diagnostic solutions. Valued at US$ 3.18 billion in 2025, it's projected to reach US$ 6.9 billion by 2032 with a CAGR of 11.67%. Modernization of healthcare systems, increasing investments in rural areas, and technological advancements such as AI integration propel this growth, with Saudi Arabia and UAE leading. Despite challenges like limited healthcare spending in some regions, initiatives in telemedicine and AI-based solutions offer significant opportunities. Notable market players include QIAGEN, Danaher, and Abbott. Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Middle East & Africa Point-of-Care Diagnostics Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (Middle East & Africa)" report has been added to Middle East and Africa (MEA) point-of-care diagnostics market is undergoing a significant transformation, driven by increasing demand for rapid, accessible, and reliable diagnostic solutions. As healthcare systems across the region continue to modernize, the market is expected to grow from an estimated US$ 3.18 billion in 2025 to US$ 6.9 billion by 2032, registering a robust compound annual growth rate (CAGR) of 11.67% during the forecast point-of-care (POC) diagnostics market in MEA is gaining traction, supported by growing awareness of early disease detection, rising healthcare spending in key nations, and the integration of innovative technologies. Countries like Saudi Arabia and the United Arab Emirates are at the forefront of this growth, with government initiatives driving the adoption of modern healthcare technologies, including POC limited access to centralized diagnostic laboratories and high healthcare costs posed challenges to market expansion. However, recent advancements in portable diagnostic devices, along with rising healthcare awareness and increased mobile health adoption, have enabled POC solutions to become more widespread, especially in underserved and remote Market DriversPrevalence of Infectious and Chronic DiseasesThe MEA region continues to grapple with a high burden of infectious diseases like HIV, tuberculosis, and influenza, along with a sharp increase in non-communicable diseases such as diabetes and cardiovascular conditions. POC diagnostics have emerged as a vital tool in enabling timely and accurate diagnosis, helping healthcare providers address these challenges more for Rapid and Accurate Diagnostic ToolsThe increasing need for fast diagnostic results, especially in rural and resource-constrained environments, is fueling the adoption of POC technologies. These tools help in faster decision-making, efficient patient management, and improved treatment outcomes, especially during health emergencies and disease Digitalization and AI IntegrationTechnological advancements, including the use of artificial intelligence (AI) and machine learning in diagnostics, are enhancing the accuracy and speed of POC testing. These innovations allow for real-time data analysis and personalized diagnostic support, making diagnostics more precise and OpportunitiesTelemedicine and Mobile Health ExpansionThe convergence of POC diagnostics with telemedicine and mobile health applications is creating new avenues for growth. With the widespread use of smartphones and internet connectivity across MEA, healthcare delivery is becoming increasingly digitized, allowing patients in remote areas to access timely diagnostic services without visiting a in Rural and Underserved RegionsGovernments and non-governmental organizations are actively investing in healthcare infrastructure across rural regions. POC diagnostics are particularly beneficial in these areas, eliminating the need for long-distance travel to centralized labs and ensuring faster treatment initiation. These investments are likely to further unlock the market's growth of AI-Based POC SolutionsAI-powered diagnostic tools are revolutionizing how diseases are detected and managed at the point of care. Their integration with wearable devices and mobile platforms will enable real-time monitoring and predictive analytics, enhancing the overall value proposition of POC diagnostics. Market RestraintsDespite the promising growth outlook, the MEA point-of-care diagnostics market faces certain challenges. Limited healthcare spending in some African nations restricts access to advanced diagnostic technologies. The high initial cost and maintenance requirements of POC devices further hinder their adoption. Additionally, insufficient reimbursement frameworks and lack of trained professionals remain concerns in achieving broader market AnalysisSaudi Arabia remains the dominant player in the Middle East and Africa point-of-care diagnostics market. The country's healthcare modernization efforts, supported by strategic government policies, are leading to an increased demand for rapid and efficient diagnostics. The UAE also demonstrates a strong growth trajectory, driven by rising healthcare awareness and private sector contrast, several regions within Africa are still hampered by low healthcare spending and limited access to diagnostic tools. However, the growing focus on universal healthcare and global support for improving healthcare systems in these regions are expected to catalyze growth in the long AnalysisThe competitive Analysis of the MEA point-of-care diagnostics market is marked by both global healthcare leaders and emerging regional players. Companies are increasingly focusing on strategic partnerships, mergers, and investments in innovative diagnostic technologies to expand their market players operating in the region include: QIAGEN Danaher Corporation F. Hoffmann-La Roche Ltd BD (Becton Dickinson) Abbott BIOMERIEUX Nova Biomedical Werfen Trividia Health, Inc. Siemens Healthcare Private Limited Market Segmentation By Product: Infectious Disease Glucose Monitoring Hepatitis C HIV Testing Sexually Transmitted Disease (STD) Influenza Respiratory Infection Tropical Disease Healthcare-Associated Infection (HAI) Pregnancy and Fertility Tumor/Cancer Marker Cardiometabolic Cholesterol Coagulation Hematology Urinalysis Other Infectious Diseases By Prescription Mode: Prescription-based Over-the-counter (OTC) By Type: Consumables and Kits Software and Services Devices Accessories By End User: Hospitals Ambulatory Care Settings Home Care Research Laboratories Others By Country: Kingdom of Saudi Arabia United Arab Emirates South Africa Rest of Gulf Cooperation Council Rest of Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
34 minutes ago
- Yahoo
Biosensors Industry Forecast Report 2025-2034 - The U.S. Biosensors Market Thrives Amid Regulatory Challenges with Innovation and Partnerships Fuelling Expansion
The demand for portable biosensors is escalating, notably in Asia-Pacific and Europe, fueled by chronic disease management needs, such as diabetes and cardiovascular monitoring. Industry growth is supported by technological advancements, increased R&D, and strategic collaborations. Biosensors Market Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "Biosensors Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to Global Biosensors Market was valued at USD 32.3 billion in 2024 and is estimated to grow at a CAGR of 7.9% to reach USD 68.5 billion by 2034, driven by increasing applications of biosensors across several sectors, particularly healthcare, where they play a crucial role in detecting biological signals. Additionally, the expanding use of biosensors in drug discovery and biomedicine further supports the market's growth. The growing demand for portable biosensors, especially in regions like Asia-Pacific and Europe, alongside technological advancements, is key factor propelling the industry. Another key factor driving the growth of the biosensors market is the increasing prevalence of chronic conditions, such as diabetes and cardiovascular diseases, which require continuous monitoring and management to avoid serious complications. For example, diabetes, if left unmanaged, can lead to severe health issues like kidney failure, stroke, or lower limb amputations. This has led to a growing demand for devices that can offer real-time monitoring of blood glucose levels, allowing patients to take immediate action when necessary. In addition to diabetes, cardiovascular diseases are also on the rise, creating an increasing need for early detection and ongoing management through advanced diagnostic tools like biosensors. These technologies are helping improve patient outcomes by providing timely data that allows for more precise treatment non-wearable biosensor segment accounted for USD 20.7 billion in 2024. These sensors, integrated into diagnostic devices used for point-of-care testing, are valued for their ease of use, high accuracy, and ability to provide immediate results without continuous user interaction. As healthcare providers seek efficient and timely diagnostic tools, the demand for these non-wearable devices is expected to rise. Technological innovations such as improved sensitivity, miniaturization, and digital connectivity enhance their effectiveness and usability in clinical electrochemical biosensor segment holds a substantial share of the market, representing 41.6% share, which was USD 13.4 billion in 2024. These biosensors are widely used in medical devices such as glucose meters for diabetic patients and in systems that monitor cardiac biomarkers and blood gases. The increasing prevalence of chronic conditions, including cardiovascular diseases and diabetes, drives the demand for electrochemical sensors as essential diagnostic States Biosensors Market generated USD 10.2 billion in 2024, driven by the rising number of chronic disease cases, especially diabetes and heart-related conditions. Despite a strict regulatory environment, the U.S. remains a hub for the development, approval, and commercialization of innovative medical technologies, including biosensors. Regulatory bodies like the FDA are increasingly focused on accelerating the approval process for new biosensor technologies, recognizing their critical role in improving healthcare strengthen their position in the market, companies are focusing on innovation and partnerships. Many firms invest heavily in R&D to develop more advanced biosensor technologies with greater sensitivity and precision. Collaborations with healthcare providers and research institutions help in driving innovation. Furthermore, some companies are working to expand their product portfolios to cater to various medical needs, such as disease-specific biosensors and wearable health monitoring devices. Market leaders, such as Thermo Fisher Scientific, Masimo, and Danaher, are adopting these strategies to enhance their market presence and remain competitive in this rapidly growing Market Analysis and Forecast Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape Competitive landscape with Porter's Five Forces and PESTEL analysis Market size, segmentation, and regional forecasts In-depth company profiles, business strategies, financial insights, and SWOT analysis Key Attributes Report Attribute Details No. of Pages 128 Forecast Period 2024-2034 Estimated Market Value (USD) in 2024 $32.3 Billion Forecasted Market Value (USD) by 2034 $68.5 Billion Compound Annual Growth Rate 7.9% Regions Covered Global Key Topics Covered Chapter 1 Methodology and ScopeChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Growing application of biosensors in medical field3.2.1.2 Rising prevalence of diabetes globally3.2.1.3 High demand for portable biosensors in Asia-Pacific and Europe3.2.1.4 Increasing technological advancements3.2.2 Industry pitfalls and challenges3.2.2.1 Stringent regulatory scenario3.2.2.2 High cost of product development3.3 Growth potential analysis3.4 Regulatory landscape3.5 Trump administration tariffs3.5.1 Impact on trade3.5.1.1 Trade volume disruptions3.5.1.2 Country-wise response3.5.2 Impact on the industry3.5.2.1 Supply-side impact (Cost of manufacturing)3.5.2.1.1 Price volatility in key materials3.5.2.1.2 Supply chain restructuring3.5.2.1.3 Production cost implications3.5.2.2 Demand-side impact (Cost to consumers)3.5.2.2.1 Price transmission to end markets3.5.2.2.2 Market share dynamics3.5.2.2.3 Consumer response patterns3.5.3 Key companies impacted3.5.4 Strategic industry responses3.5.4.1 Supply chain reconfiguration3.5.4.2 Pricing and product strategies3.5.4.3 Policy engagement3.5.5 Outlook and future considerations3.6 Technological landscape3.7 Future market trends3.8 Gap analysis3.9 Porter's analysis3.10 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, by Type, 2021-2034 ($ Mn)5.1 Key trends5.2 Wearable5.3 Non-wearableChapter 6 Market Estimates and Forecast, by Technology, 2021-2034 ($ Mn)6.1 Key trends6.2 Electrochemical6.3 Optical6.4 Thermal6.5 Piezoelectric6.6 Other technologiesChapter 7 Market Estimates and Forecast, by Applications, 2021-2034 ($ Mn)7.1 Key trends7.2 Blood glucose testing7.3 Cholesterol testing7.4 Blood gas analysis7.5 Pregnancy testing7.6 Drug discovery7.7 Infectious disease testing7.8 Other applicationsChapter 8 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)8.1 Key trends8.2 Point of care testing8.3 Home healthcare diagnostics8.4 Research laboratories8.5 Other end usersChapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)9.1 Key trends9.2 North America9.2.1 U.S.9.2.2 Canada9.3 Europe9.3.1 Germany9.3.2 UK9.3.3 France9.3.4 Spain9.3.5 Italy9.3.6 Russia9.3.7 Switzerland9.4 Asia-Pacific9.4.1 China9.4.2 Japan9.4.3 India9.5 Latin America9.5.1 Brazil9.5.2 Mexico9.6 Middle East and Africa9.6.1 South Africa9.6.2 Saudi Arabia Chapter 10 Company Profiles10.1 Abbott Laboratories10.2 ARKRAY10.3 Bio-Rad Laboratories10.4 Biosensors International Group10.5 Dexcom10.6 Danaher10.7 F. Hoffmann-La Roche10.8 Masimo10.9 Nova Biomedical10.10 Platinum Equity Advisors10.11 PHC Holdings10.12 Pinnacle Technology10.13 Siemens Healthineers10.14 Thermo Fisher Scientific10.15 Trividia HealthFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Biosensors Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900